BACKGROUND: Recent studies suggest that anti-inflammatory medication may play a role in the treatment of mood disorders. AIMS: The purpose of this study was to determine the efficacy of anti-inflammatory drugs in patients with major depressive disorder and bipolar disorder. METHOD: The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO and Clinicaltrials.gov were searched from inception until 15 April 2017 for completed and on-going randomized controlled trials of anti-inflammatory agents for major depressive disorder and bipolar disorder. Data from randomized controlled trials assessing the antidepressant and anti-manic effect of adjunctive mechanistically diverse anti-inflammatory agents were pooled to determine standard mean differences (SMDs) compared with placebo and/or treatment as usual. RESULTS: Patients receiving anti-inflammatory agents showed lower post-treatment depressive symptom scores compared with those receiving placebo with a standard mean difference of -0.71 (six randomized controlled trials, n=214, 95% CI -1.24 to -0.17, p=0.009). Anti-inflammatory treatment was found to reduce post-treatment manic symptom scores with a standard mean difference of -0.72 (three randomized controlled trials, n=96, 95% CI -1.31 to -0.13, p=0.02). Anti-inflammatories did not show a statistically significant improvement in the secondary outcome measure (change in symptom scores from baseline to outcome). CONCLUSIONS: Further high quality trials are needed before making recommendations for the routine clinical use of anti-inflammatories in the treatment of mood disorders.
BACKGROUND: Recent studies suggest that anti-inflammatory medication may play a role in the treatment of mood disorders. AIMS: The purpose of this study was to determine the efficacy of anti-inflammatory drugs in patients with major depressive disorder and bipolar disorder. METHOD: The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO and Clinicaltrials.gov were searched from inception until 15 April 2017 for completed and on-going randomized controlled trials of anti-inflammatory agents for major depressive disorder and bipolar disorder. Data from randomized controlled trials assessing the antidepressant and anti-manic effect of adjunctive mechanistically diverse anti-inflammatory agents were pooled to determine standard mean differences (SMDs) compared with placebo and/or treatment as usual. RESULTS:Patients receiving anti-inflammatory agents showed lower post-treatment depressive symptom scores compared with those receiving placebo with a standard mean difference of -0.71 (six randomized controlled trials, n=214, 95% CI -1.24 to -0.17, p=0.009). Anti-inflammatory treatment was found to reduce post-treatment manic symptom scores with a standard mean difference of -0.72 (three randomized controlled trials, n=96, 95% CI -1.31 to -0.13, p=0.02). Anti-inflammatories did not show a statistically significant improvement in the secondary outcome measure (change in symptom scores from baseline to outcome). CONCLUSIONS: Further high quality trials are needed before making recommendations for the routine clinical use of anti-inflammatories in the treatment of mood disorders.
Authors: Murray W Enns; Charles N Bernstein; Kristine Kroeker; Lesley Graff; John R Walker; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; John D Fisk; Ruth Ann Marrie Journal: PLoS One Date: 2018-06-07 Impact factor: 3.240
Authors: Vladimir M Milenkovic; Evan H Stanton; Caroline Nothdurfter; Rainer Rupprecht; Christian H Wetzel Journal: Int J Mol Sci Date: 2019-05-09 Impact factor: 5.923
Authors: Rodrigo B Mansur; Francheska Delgado-Peraza; Mehala Subramaniapillai; Yena Lee; Michelle Iacobucci; Nelson Rodrigues; Joshua D Rosenblat; Elisa Brietzke; Victoria E Cosgrove; Nicole E Kramer; Trisha Suppes; Charles L Raison; Sahil Chawla; Carlos Nogueras-Ortiz; Roger S McIntyre; Dimitrios Kapogiannis Journal: Cells Date: 2020-04-06 Impact factor: 6.600